Related Experiment Video

Updated: May 31, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Kidney cancer pathology in the new context of targeted therapy

Yves Allory1, Stéphane Culine, Alexandre de la Taille

  • 1INSERM U955, Team 7 'Translational research in genitourinary oncogenesis', Henri Mondor Hospital, AP-HP, Créteil, France. yves.allory @ hmn.aphp.fr

Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|June 17, 2011
PubMed

Insights

Metastatic renal cancer survival is poor, but targeted therapies offer improved prognosis. This review explores key molecular pathways and biomarkers for better kidney cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Translational Medicine

Background:

  • Metastatic renal cancer has a poor prognosis, with <10% 5-year survival.
  • Advances in molecular pathology have led to targeted therapies like antiangiogenic drugs and mTOR inhibitors.
  • Current targeted therapies improve outcomes but lack consistent predictive biomarkers, complicating clinical trial design.

Purpose of the Study:

  • To review key molecular pathways in renal cancer subtypes.
  • To analyze the impact of targeted therapies on these pathways.
  • To identify potential predictive biomarkers and inform future clinical trial design.

Main Methods:

  • Literature review focusing on VHL/HIF, mTOR, c-MYC, c-MET, and immune response pathways.
  • Analysis of targeted therapy effects within specific renal tumor subtypes.
  • Synthesis of information to guide biomarker discovery and trial development.

Main Results:

  • Identified critical molecular pathways (VHL/HIF, mTOR, c-MYC, c-MET, immune response) implicated in renal cancer.
  • Highlighted the intermingled nature of these pathways across different tumor subtypes.
  • Emphasized the need for predictive biomarkers to optimize targeted therapy efficacy.

Conclusions:

  • Targeted therapies have improved metastatic renal cancer prognosis but require better biomarker strategies.
  • Understanding shared and subtype-specific molecular pathways is crucial for biomarker development.
  • Future research should focus on integrated pathway analysis and biomarker-driven clinical trials for kidney cancer.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...